AZN.L - AstraZeneca PLC

LSE - LSE Delayed price. Currency in GBp
7,216.00
+113.00 (+1.59%)
At close: 4:53PM BST
Stock chart is not supported by your current browser
Previous close7,103.00
Open7,234.00
Bid7,161.00 x 0
Ask7,169.00 x 0
Day's range6,963.00 - 7,240.00
52-week range5,626.00 - 8,227.88
Volume3,606,375
Avg. volume2,717,764
Market cap94.689B
Beta (5Y monthly)0.36
PE ratio (TTM)70.33
EPS (TTM)N/A
Earnings dateN/A
Forward dividend & yield2.18 (3.07%)
Ex-dividend date27 Feb 2020
1y target estN/A
  • AstraZeneca's Imfinzi Gets FDA Nod for SCLC Label Expansion
    Zacks

    AstraZeneca's Imfinzi Gets FDA Nod for SCLC Label Expansion

    AstraZeneca's (AZN) Imfinzi gets FDA approval as first-line treatment for extensive-stage small cell lung cancer patients. A phase III study on Farxiga in CKD patients meets endpoint earlier than expected.

  • The Zacks Analyst Blog Highlights: Apple, Cisco, PepsiCo, AstraZeneca and NextEra
    Zacks

    The Zacks Analyst Blog Highlights: Apple, Cisco, PepsiCo, AstraZeneca and NextEra

    The Zacks Analyst Blog Highlights: Apple, Cisco, PepsiCo, AstraZeneca and NextEra

  • AstraZeneca scores win as diabetes drug shown to slow kidney disease
    Reuters

    AstraZeneca scores win as diabetes drug shown to slow kidney disease

    An interim study analysis showed that patients on Farxiga, known as Forxiga outside North America, had better renal function and were less likely to die from heart of kidney disease than a control group on placebo, the company said on in a statement on Monday. Farxiga, among AstraZeneca's top five drugs by sales, was first developed as a diabetes drug as it causes the kidneys to expel blood sugar from the body through urine but it has shown promise as a heart failure treatment, even among non-diabetic patients.

  • AstraZeneca's Imfinzi gets FDA nod to target small-cell lung cancer
    Reuters

    AstraZeneca's Imfinzi gets FDA nod to target small-cell lung cancer

    The treatment, when combined with chemotherapy, was approved by the U.S. Food and Drug Administration for adult patients with extensive-stage small cell lung cancer, the British drugmaker said. AstraZeneca has already carved out a niche for Imfinzi, which enables the immune system to detect and attack certain cancer cells, in the more common non-small cell lung cancer (NSCLC) setting, with approval for tumours that have only spread in the chest. In the small-cell type of cancer, Astra is seeking to catch up with Roche, whose immunotherapy Tecentriq won U.S. approval for the disease type a year ago.

  • 3 FTSE 100 dividends I’d buy during the 2020 stock market crash
    Fool.co.uk

    3 FTSE 100 dividends I’d buy during the 2020 stock market crash

    Some of the biggest FTSE 100 dividends are being cut during the Covid-19 crisis. Here's my approach to protecting long-term investing income.The post 3 FTSE 100 dividends I'd buy during the 2020 stock market crash appeared first on The Motley Fool UK.

  • £1,000 to invest? I’d buy these 3 FTSE 100 healthcare stocks!
    Fool.co.uk

    £1,000 to invest? I’d buy these 3 FTSE 100 healthcare stocks!

    FTSE 100 healthcare stocks are gearing up to combat Covid-19. Investors are honing in on them as their future potential for wealth generation grows. The post £1,000 to invest? I’d buy these 3 FTSE 100 healthcare stocks! appeared first on The Motley Fool UK.

  • AstraZeneca's Lokelma Gets Approval in Japan for Hyperkalaemia
    Zacks

    AstraZeneca's Lokelma Gets Approval in Japan for Hyperkalaemia

    The Japanese regulatory body nods to AstraZeneca's (AZN) Lokelma for addressing patients with hyperkalaemia. The company collaborates with Silence Therapeutics for siRNA therapeutics.

  • FTSE 100 companies are cancelling dividends. Here’s how I’m investing now
    Fool.co.uk

    FTSE 100 companies are cancelling dividends. Here’s how I’m investing now

    FTSE 100 stocks' dividends are becoming less reliable as the economy slows. But investors can still come out ahead. Here’s how.The post FTSE 100 companies are cancelling dividends. Here’s how I’m investing now appeared first on The Motley Fool UK.

  • AstraZeneca/Merck's Lynparza Combo Ovarian Cancer Study Fails
    Zacks

    AstraZeneca/Merck's Lynparza Combo Ovarian Cancer Study Fails

    AstraZeneca (AZN)/Merck's (MRK) study evaluating cediranib added to Lynparza fails to meet the primary endpoint of PFS in patients with platinum-sensitive relapsed ovarian cancer

  • Pharma Stock Roundup: ABBV, LLY Coronavirus Product Development Efforts, FDA Updates
    Zacks

    Pharma Stock Roundup: ABBV, LLY Coronavirus Product Development Efforts, FDA Updates

    Lilly (LLY) signs deal with AbCellera to co-develop antibody therapies to treat COVID-19. AbbVie (ABBV) supports studies evaluating Kaletra for treating COVID-19.

  • Why I’d buy AstraZeneca as the FTSE 100 crashes below 5,500
    Fool.co.uk

    Why I’d buy AstraZeneca as the FTSE 100 crashes below 5,500

    When the whole FTSE 100 is crashing, even top shares can fall heavily. Here's why I rate AstraZeneca as one of the best buys.The post Why I'd buy AstraZeneca as the FTSE 100 crashes below 5,500 appeared first on The Motley Fool UK.

  • 2 high-quality FTSE 100 shares I’d buy right now
    Fool.co.uk

    2 high-quality FTSE 100 shares I’d buy right now

    My guess is that when the COVID-19 coronavirus fades from our collective consciousness, these two stocks will be making new highs.The post 2 high-quality FTSE 100 shares I’d buy right now appeared first on The Motley Fool UK.

  • Does AstraZeneca’s share price fall make it a bargain FTSE 100 stock?
    Fool.co.uk

    Does AstraZeneca’s share price fall make it a bargain FTSE 100 stock?

    G A Chester discusses whether the AstraZeneca share price is a terrific 'dip buy', or if there are valuation issues with this popular FTSE 100 stock.The post Does AstraZeneca's share price fall make it a bargain FTSE 100 stock? appeared first on The Motley Fool UK.

  • Reuters - UK Focus

    LIVE MARKETS-Rising euro delivers double whammy for STOXXE

    * Bourses fall in virus worries * Europe's bank at lowest since 2009 Welcome to the home for real-time coverage of European equity markets brought to you by Reuters stocks reporters. You can share your thoughts with Thyagaraju Adinarayan (thyagaraju.adinarayan@tr.com), Joice Alves (joice.alves@tr.com), Julien Ponthus (julien.ponthus@tr.com) in London. The currency has actually been on fire since the coronavirus started shaking global market and the dollar sunk after the Fed cut.

  • Reuters - UK Focus

    LIVE MARKETS-Stock picking tips

    * Bourses fall in virus worries * Europe's bank at lowest since 2009 Welcome to the home for real-time coverage of European equity markets brought to you by Reuters stocks reporters. You can share your thoughts with Thyagaraju Adinarayan (thyagaraju.adinarayan@tr.com), Joice Alves (joice.alves@tr.com), Julien Ponthus (julien.ponthus@tr.com) in London. STOCK PICKING TIPS (1540 GMT) Here are some stock picking tip from BNP Paribas' Edmund Shing.

  • Reuters - UK Focus

    LIVE MARKETS-European banks at lowest since 2009

    You can share your thoughts with Thyagaraju Adinarayan (thyagaraju.adinarayan@tr.com), Joice Alves (joice.alves@tr.com), Julien Ponthus (julien.ponthus@tr.com) in London. Seems there's a combination of straight recession fears (with all that means in terms of toxic NPLs quickly building up) and expectations of another ECB cut which would bite hard into margins again.

  • Reuters - UK Focus

    MORNING BID-Between stimulus euphoria and virus dejection

    Two-year U.S. Treasury yields have dropped almost 85 bps in the past two weeks – their biggest two-week drop since 1987. The slide in U.S. Treasury yields further eroded the dollar's interest rate advantage.

  • Reuters - UK Focus

    London stocks hammered as Britain records first virus death

    UK stocks fell again on Friday as growing economic risks from the coronavirus outbreak shattered investor confidence, with Britain recording its first death from the pathogen. A 1.5% fall for the FTSE 100 erased the blue-chip index's gains from earlier this week. Britain said an older person with underlying health problems had succumbed to the flu-like virus on Thursday, while the number of infections jumped to 115.

  • £5k to invest? Here are 2 FTSE 100 dividend stocks I’d buy right now
    Fool.co.uk

    £5k to invest? Here are 2 FTSE 100 dividend stocks I’d buy right now

    These FTSE 100 income stocks have fallen in value, but their long-term outlook has only improved. The post £5k to invest? Here are 2 FTSE 100 dividend stocks I'd buy right now appeared first on The Motley Fool UK.

  • Read This Before Selling AstraZeneca PLC (LON:AZN) Shares
    Simply Wall St.

    Read This Before Selling AstraZeneca PLC (LON:AZN) Shares

    We often see insiders buying up shares in companies that perform well over the long term. Unfortunately, there are...

  • AbbVie-Allergan $63 billion deal aided by Nestle, AstraZeneca buys
    Reuters

    AbbVie-Allergan $63 billion deal aided by Nestle, AstraZeneca buys

    U.S. drugmaker AbbVie's $63 billion tie-up with Allergan is getting help from Nestle and AstraZeneca buying up products the Irish-domiciled company is shedding to placate regulators. AbbVie is swallowing Allergan to give it control of the lucrative wrinkle treatment Botox and to diversify a portfolio heavily dependent on its $19-billion-per-year arthritis drug Humira, the world's best-selling medicine that is advancing toward U.S. patent expiration. Swiss food group Nestle bulked up its medical nutrition business with Allergan's Zenpep, a product with 2018 sales of $237 million which treats people whose pancreases do not provide enough enzymes to digest fats, proteins and sugars.

  • Reuters - UK Focus

    AbbVie-Allergan $63 bln deal aided by Nestle, AstraZeneca buys

    U.S. drugmaker AbbVie's $63 billion tie-up with Allergan is getting help from Nestle and AstraZeneca buying up products the Irish-domiciled company is shedding to placate regulators. AbbVie is swallowing Allergan to give it control of the lucrative wrinkle treatment Botox and to diversify a portfolio heavily dependent on its $19-billion-per-year arthritis drug Humira, the world's best-selling medicine that is advancing toward U.S. patent expiration. Swiss food group Nestle bulked up its medical nutrition business with Allergan's Zenpep, a product with 2018 sales of $237 million which treats people whose pancreases do not provide enough enzymes to digest fats, proteins and sugars.

  • Health stocks reverse coronavirus gains as one analyst says the market is overreacting
    Yahoo Finance

    Health stocks reverse coronavirus gains as one analyst says the market is overreacting

    Virus originating in Wuhan, China affected stock markets Tuesday, but one analyst said reactions were too strong.

By using Yahoo, you agree that we and our partners can use cookies for purposes such as customising content and advertising. See our Privacy Policy to learn more